Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELACS: Early versus later restart of oral anticoagulation after chronic subdural hematoma surgery in patients with atrial fibrillation
2025-521179-29-00Phase 3Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of apixaban, dabigatran, edoxaban, rivaroxaban and warfarin in Atrial fibrillation (AFib) (2 arms), sponsored by Helsinki University Hospital. Primary endpoints: Composite primary outcome, Thromboembolic events and 2 more. Planned start Jul 2025; status: authorised.
02
Drugs
apixabandabigatranedoxabanrivaroxabanwarfarin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2025-521179-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521179-29-00.